Forum Financial Management LP Acquires 65,399 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Forum Financial Management LP grew its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 133.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 114,324 shares of the company’s stock after acquiring an additional 65,399 shares during the quarter. Forum Financial Management LP’s holdings in Takeda Pharmaceutical were worth $1,514,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Public Employees Retirement System of Ohio bought a new stake in shares of Takeda Pharmaceutical during the third quarter valued at approximately $601,000. QRG Capital Management Inc. raised its stake in shares of Takeda Pharmaceutical by 16.8% in the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company’s stock valued at $4,364,000 after buying an additional 47,490 shares in the last quarter. Versant Capital Management Inc acquired a new stake in shares of Takeda Pharmaceutical during the 4th quarter valued at about $26,000. Franklin Resources Inc. bought a new stake in Takeda Pharmaceutical in the third quarter valued at about $244,000. Finally, US Bancorp DE raised its position in Takeda Pharmaceutical by 21.2% in the fourth quarter. US Bancorp DE now owns 124,332 shares of the company’s stock worth $1,646,000 after purchasing an additional 21,744 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK opened at $14.69 on Friday. The business has a fifty day moving average of $14.57 and a 200-day moving average of $13.91. The firm has a market cap of $46.73 billion, a PE ratio of 36.71, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.37.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.